- Trials with a EudraCT protocol (160)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
160 result(s) found for: tiotropium.
Displaying page 1 of 8.
EudraCT Number: 2007-005107-17 | Sponsor Protocol Number: 1184.15 | Start Date*: 2008-01-28 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim bv | ||||||||||||||||||
Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal... | ||||||||||||||||||
Medical condition: Moderate to severe COPD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) FR (Completed) SE (Prematurely Ended) DK (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) SK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005134-36 | Sponsor Protocol Number: 1184.14 | Start Date*: 2008-01-28 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim bv | ||||||||||||||||||
Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal... | ||||||||||||||||||
Medical condition: Moderate to severe COPD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) PT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) DK (Completed) FR (Completed) SE (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) GR (Completed) LT (Prematurely Ended) EE (Prematurely Ended) SK (Completed) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001801-29 | Sponsor Protocol Number: 1298.3 | Start Date*: 2011-10-26 |
Sponsor Name:Boehringer Ingelheim | ||
Full Title: A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Ti... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002275-28 | Sponsor Protocol Number: 1237.19 | Start Date*: 2014-11-18 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compar... | |||||||||||||
Medical condition: chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) BE (Completed) NL (Completed) HU (Completed) GB (Completed) ES (Completed) AT (Completed) IE (Completed) LT (Completed) CZ (Completed) LV (Completed) SK (Completed) DE (Completed) SI (Completed) GR (Completed) BG (Completed) HR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015713-51 | Sponsor Protocol Number: 205.452 | Start Date*: 2010-06-09 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG, Medical Affairs Germany | |||||||||||||
Full Title: A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) FI (Completed) LV (Completed) HU (Completed) NO (Completed) LT (Completed) SK (Completed) SE (Completed) ES (Completed) NL (Completed) DK (Completed) PT (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) BG (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000207-15 | Sponsor Protocol Number: 1184.24 | Start Date*: 2008-02-26 | |||||||||||
Sponsor Name:Boehringer Ingelheim bv | |||||||||||||
Full Title: A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000114-22 | Sponsor Protocol Number: CQVA149A2316 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 μg o.d.) + salmeterol/fluticasone propionate FDC... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) EE (Completed) NL (Completed) LV (Completed) LT (Completed) DE (Completed) CZ (Completed) HU (Completed) DK (Completed) SK (Completed) ES (Completed) AT (Completed) PL (Completed) GR (Completed) HR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016251-21 | Sponsor Protocol Number: 205.458 | Start Date*: 2010-10-29 | |||||||||||
Sponsor Name:Boehringer Ingelheim | |||||||||||||
Full Title: Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013763-19 | Sponsor Protocol Number: CQAB149BIT01 | Start Date*: 2009-09-24 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD p... | |||||||||||||
Medical condition: moderate COPD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004710-42 | Sponsor Protocol Number: 1237.20 | Start Date*: 2012-04-23 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination... | |||||||||||||
Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) DK (Completed) BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001495-69 | Sponsor Protocol Number: 2008/0801 | Start Date*: 2008-07-11 |
Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille | ||
Full Title: Réversibilité sous Tiotropium (SPIRIVA®) chez les patients BPCO : paramètres EFR, dyspnée et TDM | ||
Medical condition: Traitement bronchodilatateur continu destiné à soulager les symptômes des patients présentant une bronchopneumopathie chronique obstructive (BPCO). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003413-33 | Sponsor Protocol Number: TBB-COPD-201 | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI)... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007944-33 | Sponsor Protocol Number: CQAB149B2348 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 μg o.d. vs inhaled tiotropium 18 μg o.d... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) FI (Completed) SK (Completed) CZ (Completed) LT (Completed) IS (Completed) BE (Completed) PT (Completed) EE (Completed) DK (Completed) LV (Completed) HU (Completed) DE (Completed) FR (Completed) NL (Completed) PL (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005087-26 | Sponsor Protocol Number: 1237.4 | Start Date*: 2008-06-25 | |||||||||||
Sponsor Name:Boehringer Ingelheim GmbH & Co. KG | |||||||||||||
Full Title: Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002264-24 | Sponsor Protocol Number: 1237.26 | Start Date*: 2013-11-14 | |||||||||||
Sponsor Name:Boehringer Ingelheim AB | |||||||||||||
Full Title: A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) SK (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019047-19 | Sponsor Protocol Number: 03-2010 | Start Date*: 2010-05-10 |
Sponsor Name:Pneumologia c/o Villa Pineta | ||
Full Title: ADDITIONAL EFFECT OF TIOTROPIUM BROMIDE ON EXERCISE TOLERANCE IN COPD PATIENTS. PILOT STUDY | ||
Medical condition: COPD (Chronic Obstructive Pulmonary Disease) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-010668-40 | Sponsor Protocol Number: 1237.5 | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:Boehringer Ingelheim bv [...] | |||||||||||||
Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μ... | |||||||||||||
Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FI (Completed) PT (Completed) SI (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) EE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010669-22 | Sponsor Protocol Number: 1237.6 | Start Date*: 2011-09-19 | |||||||||||
Sponsor Name: [...] | |||||||||||||
Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium plus olodaterol fixed dose combination (2.5 μg / ... | |||||||||||||
Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) SE (Completed) ES (Completed) SK (Completed) BE (Completed) DE (Completed) HU (Completed) IE (Completed) AT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003879-29 | Sponsor Protocol Number: 1237.49 | Start Date*: 2015-12-30 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 µg) delivered by the Respimat® inhaler versus the... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) AT (Completed) SI (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018471-26 | Sponsor Protocol Number: 205.380 | Start Date*: 2010-10-12 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.... | |||||||||||||
Medical condition: moderate persistent asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
